Incyte Submits New Drug Application for Ruxolitinib in Myelofibrosis to the US Food and Drug Administration
Links shared publicly online about this topic.
- 230total visits
Incyte Submits New Drug Application for Ruxolitinib in Myelofibrosis to the US Food and Drug Administration
Ruxolitinib is a new drug in development for the treatment of myelofibrosis. Ruxolitinib information includes news, clinical trial results and side effects.
View full resource at drugs.com
Tags: Diet and Nutrition, Drug, Clinical Trial, FDA, News
Most Recently Shared on June 10, 2011 at 2:02 am By:
Incyte Submits New Drug Application for Ruxolitinib in Myelofibrosis to the US Food and Drug Administratio... http://bit.ly/kCHd2A #drug
Advertisement
